iCad (Nasdaq:ICAD) today announced plans to present new studies validating its AI-powered ProFound Breast Health Suite.
ProFound helps to uncover hidden heart or vascular disease and predict a woman’s risk for developing breast cancer in the next 1-2 years. The platform can screen a single mammogram for two of the top causes of death for women. iCad designed it to improve accuracy, streamline clinical workflow and deliver results more quickly.
The company plans to present its findings at RSNA23.
“The ProFound Breast Health Suite significantly increases cancer detection rates with up to 2x enhanced clinical performance compared to other AI platforms, and reduces the rate of false positive results while accurately evaluating a woman’s breast density and cancer risk,” said Dana Brown, president and CEO of iCad, Inc. “Our growing body of important research illustrates the potential our newest solution, ProFound Heart Health, holds for the assessment of…